Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 135

1.

Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim.

Samaras P, Blickenstorfer M, Siciliano RD, Haile SR, Buset EM, Petrausch U, Mischo A, Honegger H, Schanz U, Stussi G, Stahel RA, Knuth A, Stenner-Liewen F, Renner C.

Ann Hematol. 2011 Jan;90(1):89-94. doi: 10.1007/s00277-010-1036-8. Epub 2010 Aug 13.

PMID:
20706722
[PubMed - indexed for MEDLINE]
2.

Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients.

Martino M, Praticò G, Messina G, Irrera G, Massara E, Messina G, Console G, Iacopino P.

Eur J Haematol. 2006 Nov;77(5):410-5. Epub 2006 Aug 23.

PMID:
16930141
[PubMed - indexed for MEDLINE]
3.

Pegfilgrastim to accelerate neutrophil engraftment following peripheral blood stem cell transplant and reduce the duration of neutropenia, hospitalization, and use of intravenous antibiotics: a phase II study in multiple myeloma and lymphoma and comparison with filgrastim-treated matched controls.

Wannesson L, Luthi F, Zucca E, Rosselet-Christ A, Baglioni M, Marelli L, Ghielmini M, Ketterer N.

Leuk Lymphoma. 2011 Mar;52(3):436-43. doi: 10.3109/10428194.2010.545462.

PMID:
21323524
[PubMed - indexed for MEDLINE]
4.

Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.

Kroschinsky F, Hölig K, Platzbecker U, Poppe-Thiede K, Ordemann R, Blechschmidt M, Oelschlaegel U, Schaich M, Hänel M, Bornhäuser M, Ehninger G.

Transfusion. 2006 Aug;46(8):1417-23.

PMID:
16934080
[PubMed - indexed for MEDLINE]
5.

Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.

Milano-Bausset E, Gaudart J, Rome A, Coze C, Gentet JC, Padovani L, Lacarelle B, André N.

Clin Ther. 2009;31 Pt 2:2388-95. doi: 10.1016/j.clinthera.2009.11.013.

PMID:
20110048
[PubMed - indexed for MEDLINE]
6.

Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma.

Fenk R, Hieronimus N, Steidl U, Bruns I, Graef T, Zohren F, Ruf L, Haas R, Kobbe G.

Exp Hematol. 2006 Oct;34(10):1296-302.

PMID:
16982322
[PubMed - indexed for MEDLINE]
7.

Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation.

Gerds A, Fox-Geiman M, Dawravoo K, Rodriguez T, Toor A, Smith S, Kiley K, Fletcher-Gonzalez D, Hicks C, Stiff P.

Biol Blood Marrow Transplant. 2010 May;16(5):678-85. doi: 10.1016/j.bbmt.2009.12.531. Epub 2010 Jan 4.

PMID:
20045479
[PubMed - indexed for MEDLINE]
8.

Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study.

Jagasia MH, Greer JP, Morgan DS, Mineishi S, Kassim AA, Ruffner KL, Chen H, Schuening FG.

Bone Marrow Transplant. 2005 Jun;35(12):1165-9.

PMID:
15880129
[PubMed - indexed for MEDLINE]
9.

Delayed administration of filgrastim (G-CSF) following autologous peripheral blood stem cell transplantation (APBSCT) in pediatric patients does not change time to neutrophil engraftment and reduces use of G-CSF.

Pai V, Fernandez SA, Laudick M, Rosselet R, Termuhlen A.

Pediatr Blood Cancer. 2010 May;54(5):728-33. doi: 10.1002/pbc.22394.

PMID:
20063422
[PubMed - indexed for MEDLINE]
11.

Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation.

Samaras P, Buset EM, Siciliano RD, Haile SR, Petrausch U, Mischo A, Honegger H, Pestalozzi BC, Schanz U, Stussi G, Stahel RA, Knuth A, Renner C, Stenner-Liewen F.

Oncology. 2010;79(1-2):93-7. doi: 10.1159/000320604. Epub 2010 Nov 15.

PMID:
21079406
[PubMed - indexed for MEDLINE]
12.

Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-SCT patients.

Mathew S, Adel N, Rice RD, Panageas K, Duck ET, Comenzo RL, Kewalramani T, Nimer SD.

Bone Marrow Transplant. 2010 Oct;45(10):1522-7. doi: 10.1038/bmt.2009.373. Epub 2010 Jan 11.

PMID:
20062102
[PubMed - indexed for MEDLINE]
13.

Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices.

Morrison VA, Wong M, Hershman D, Campos LT, Ding B, Malin J.

J Manag Care Pharm. 2007 May;13(4):337-48.

PMID:
17506600
[PubMed - indexed for MEDLINE]
Free Article
14.

Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma.

Rifkin R, Spitzer G, Orloff G, Mandanas R, McGaughey D, Zhan F, Boehm KA, Asmar L, Beveridge R.

Clin Lymphoma Myeloma Leuk. 2010 Jun;10(3):186-91. doi: 10.3816/CLML.2010.n.029.

PMID:
20511163
[PubMed - indexed for MEDLINE]
15.

Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.

Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, Weisdorf DJ.

Biol Blood Marrow Transplant. 2004 Jun;10(6):395-404.

PMID:
15148493
[PubMed - indexed for MEDLINE]
16.

Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.

Perrier L, Lefranc A, Pérol D, Quittet P, Schmidt-Tanguy A, Siani C, de Peretti C, Favier B, Biron P, Moreau P, Bay JO, Lissandre S, Jardin F, Espinouse D, Sebban C.

Appl Health Econ Health Policy. 2013 Apr;11(2):129-38. doi: 10.1007/s40258-013-0011-7.

PMID:
23435861
[PubMed - indexed for MEDLINE]
17.

A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation.

Bence-Bruckler I, Bredeson C, Atkins H, McDiarmid S, Hamelin L, Hopkins H, Perry G, Genest P, Huebsch L.

Bone Marrow Transplant. 1998 Nov;22(10):965-9.

PMID:
9849693
[PubMed - indexed for MEDLINE]
Free Article
18.

High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.

Martino M, Console G, Irrera G, Praticò G, Stelitano C, Callea V, Morabito F, Quartarone E, Musolino C, Piro E, Brugiatelli M, Iacopino P.

Am J Hematol. 2006 Dec;81(12):973-8.

PMID:
16888786
[PubMed - indexed for MEDLINE]
19.

Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy.

Tricot G, Barlogie B, Zangari M, van Rhee F, Hoering A, Szymonifka J, Cottler-Fox M.

Haematologica. 2008 Nov;93(11):1739-42. doi: 10.3324/haematol.13204. Epub 2008 Aug 25.

PMID:
18728024
[PubMed - indexed for MEDLINE]
Free Article
20.

Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma.

Steidl U, Fenk R, Bruns I, Neumann F, Kondakci M, Hoyer B, Gräf T, Rohr UP, Bork S, Kronenwett R, Haas R, Kobbe G.

Bone Marrow Transplant. 2005 Jan;35(1):33-6.

PMID:
15531906
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk